Sterling Private Medical Review: What the GLP-1 Subscription Terms Actually Say

A subscription can look simple on a treatment page and become more complicated when the next payment approaches. Sterling Private Medical illustrates that tension: its treatment pages describe cancellation with 30 days’ notice, while its terms describe switching off automatic refills at least 48 hours before monthly processing. Those are materially different instructions for someone trying to avoid another charge. This documentary review focuses on what a prospective customer would be agreeing to, not whether a particular treatment is appropriate.

Sterling markets injectable semaglutide, injectable tirzepatide and a GLP-1 Microdose program through a concierge telehealth model. Its public presentation emphasizes physician direction, discreet delivery and ongoing support. The terms, however, define Sterling as an intermediary rather than the organization providing clinical care or dispensing medication. Public documentation consulted October 19, 2026, establishes several concrete offerings and obligations, but leaves important questions about final prices, participating organizations and cancellation unresolved. Those distinctions matter more than the simplicity of the advertised monthly fee.

At a glance

Advertised starting prices: Injectable semaglutide starts at $169/month, injectable tirzepatide at $199/month and GLP-1 Microdose at $129/month; final pricing is confirmed after consultation.
Sources: [4]
Recurring payment authorization: A recurring monthly order authorizes an immediate charge and subsequent charges every 30 days until canceled, with electronic notice 5–7 days before a scheduled transaction.
Sources: [8]
Conflicting cancellation instructions: Treatment pages require 30 days’ notice before the next billing cycle; the terms allow cancellation by disabling auto-refill at least 48 hours before monthly processing.
Sources: [3] [8]
Separate clinical and pharmacy responsibilities: Sterling’s terms say it does not provide clinical care, prepare or dispense medication, or control independent providers’ and pharmacies’ professional judgment.
Sources: [8]
Pharmacy-channel restriction: Purchasing a prescription-containing service requires accepting fulfillment through a pharmacy accessible through the platform and waiving pharmacy choice under the stated terms.
Sources: [8]

Resolve the cancellation conflict before the first payment

The most consequential contract issue is not hidden pricing; it is inconsistent instructions about stopping renewal. Sterling’s semaglutide page says memberships may be canceled with 30 days’ notice before the next billing cycle. Its terms instead say a subscription may be canceled by turning off auto-refill in the user portal up to 48 hours before the applicable monthly processing date. The consulted documentation does not explain whether these provisions apply to different circumstances or which governs when they conflict.

A prospective customer should request written confirmation of the applicable deadline, the precise processing date and the action that completes cancellation. The portal instruction is more specific than a general request to contact support, but that does not resolve the competing 30-day language. Save the response and the cancellation confirmation. Our guide to cancellation notice and renewal dates explains why the date a request is sent, the date renewal is disabled and an existing order’s status can be separate questions.

Refund language creates another boundary. The treatment page says consultations, medical visits and fulfilled prescriptions are nonrefundable once services begin or medication is processed. Ending future automatic payments therefore should not be treated as reversing services already delivered or an order already processed. The public wording does not establish a general money-back guarantee, and it does not resolve what happens to every component of the bundled charge if treatment is not prescribed.

Sources: [3] [8]

What the advertised price buys—and what remains unsettled

Sterling publishes three starting prices rather than one universal membership rate. Injectable semaglutide begins at $169 per month and injectable tirzepatide at $199; the GLP-1 Microdose program begins at $129. Each listing advertises medication, supplies, discreet delivery and 24/7 concierge care and check-ins. The microdose listing does not identify its active ingredient or route in the consulted documentation, so it should not be treated as a clearly specified lower-priced version of either injectable program.

The homepage says final pricing is confirmed after consultation and describes medication, provider care and concierge support as included in the monthly fee. The semaglutide page additionally promises no consultation charges or dose-change surcharges. These are useful commercial commitments, but they do not explain what determines a quote above the starting amount. Nor do the consulted pages clearly settle laboratory costs, testing, in-person care or separately itemized shipping charges.

The terms explain that the subscription bundles pharmacy, medical-group and platform fees, with Sterling collecting the first two on those organizations’ behalf. Ask for the final amount and inclusions in writing before authorizing payment. Sterling advertises a no-insurance model; that is not evidence of insurer reimbursement or a particular benefit exclusion. Its public material also does not document an introductory-versus-renewal price schedule, a prepaid alternative or a quantified medication supply per shipment.

Published prices and payment conditions
Offering or term	Published amount or interval	Important qualification
Semaglutide injection	From $169/month	Medication and supplies advertised as included; final quote follows consultation.
Tirzepatide injection	From $199/month	Medication and supplies advertised as included; not a universal patient price.
GLP-1 Microdose	From $129/month	Medication and supplies advertised as included; ingredient and route are not specified.
Recurring order	Immediately, then every 30 days	Continues until canceled; every 30 days is not the same as a calendar month.
Advance transaction notice	5–7 days before processing	Notice does not resolve the conflicting cancellation deadlines.

Sources: [4] [3] [8]

The first charge starts a recurring authorization

Sterling’s recurring-order provision authorizes charging the amount listed on the applicable purchase page immediately and every 30 days thereafter until cancellation. That is more specific than the marketing shorthand “monthly.” A 30-day interval does not necessarily fall on the same date each calendar month. The terms also promise an electronic notification five to seven days before a scheduled transaction and a receipt after a successful charge.

The notification is useful, but it should not be mistaken for a new consent request before each payment. The underlying authorization is recurring. Also, a notice five to seven days before processing would arrive inside the treatment page’s stated 30-day cancellation window, even though it precedes the terms’ 48-hour cutoff. That mismatch makes it especially important to settle the applicable rule before relying on a reminder to make the decision.

The consulted documentation does not establish a fixed minimum subscription term or the quantity and duration of medication in each shipment. A recurring billing interval alone answers neither question. Before purchase, distinguish the payment schedule from the medication schedule and ask how changes, pauses or a clinician’s decision against continued prescribing affect the next charge. Our explanation of monthly prices and ongoing commitments provides a framework for separating those obligations.

Sources: [8] [3]

A concierge brand with independent care organizations

Sterling describes itself publicly as a private concierge telehealth practice for weight, hormones and healthy aging, serving men and women. It also advertises hormone optimization, with GLP-1 programs booked online and other services arranged directly with a physician. The legal description is narrower: a platform facilitating access to independent clinical providers and compounding pharmacies. Claims that those providers are U.S. board-certified and pharmacies state-licensed are the site’s representations, not credentials independently verified in this review.

The terms expressly say Sterling does not practice medicine, provide clinical care, prepare or dispense medication, or direct the professional judgment of providers and pharmacies. For a customer, that division means the organization collecting a bundled payment is not necessarily the organization responsible for a prescription decision or pharmacy preparation. The consulted documentation does not identify the participating clinicians, medical groups or dispensing pharmacies by name.

Enrollment requires an account with a username and password. The advertised care pathway starts with a short assessment of goals and basic medical history, followed by review by a licensed clinician and a plan if clinically appropriate. The terms require a consultation, a provider’s determination of appropriateness and an issued prescription before medication can be obtained. Completing enrollment is therefore not a promise of a prescription. Use our guide to platform, clinician and pharmacy responsibilities to organize questions about who handles each obligation.

Sources: [5] [4] [8]

Eligibility and geography are conditions, not guarantees

Sterling’s semaglutide and tirzepatide pages describe candidates as adults 18 or older with a BMI of at least 27, or at least 25 with weight-related conditions. These are Sterling’s published screening criteria, not an individualized eligibility determination. Its BMI calculator is expressly educational, and the site says a licensed provider makes the treatment decision. The terms also require customers to be at least 18 or the age of majority where they live, if higher.

The semaglutide page lists exclusions including personal or family history of medullary thyroid carcinoma or MEN 2; pregnancy, breastfeeding or planning pregnancy; and active pancreatitis or untreated severe gastrointestinal disease. Separately, the microdose page markets its program to people near their goal weight, those reporting poor tolerance of standard GLP-1 treatment and people incorporating it into broader hormone or healthy-aging care. Those descriptions do not establish suitability, improved tolerance or proven outcomes for an individual.

Geography adds another enrollment condition. During a consultation, the terms require physical presence in the same state as the shipping address on the account. Although Sterling advertises national coverage, availability remains subject to state-specific regulations and may change. The consulted documentation does not provide an operational state-by-state list or availability by medication. Anyone planning travel or using an address different from their current location should clarify the arrangement before booking, rather than treating national marketing as confirmation.

Sources: [3] [9] [10] [4] [8]

The pharmacy arrangement limits choice

Sterling describes compounded medication prepared by U.S. partner compounding pharmacies and shipped on a structured cadence, without quantifying that schedule. Its disclaimer places custom compounding in circumstances where commercially available treatments do not meet an individual patient’s needs. The contract also imposes a meaningful channel restriction: purchasing a service containing a prescription requires accepting fulfillment through the platform’s pharmacy arrangement and waiving the ability to choose another pharmacy.

Sterling acknowledges that compounded medications are not FDA approved and that FDA has not independently verified their safety, efficacy and quality. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence, but neither advertising nor a clearly written contract establishes that Sterling’s compounded products reproduce results from trials of approved products.

Delivery is advertised as direct to the home in temperature-controlled, unmarked packaging. The terms separately warn that prescription products will not be dispensed in child-resistant containers—an important practical distinction from discreet outer packaging. No firm preparation, dispatch or arrival timetable is documented. FDA advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Before ordering, establish who receives a delivery complaint and how replacement or payment questions are handled.

Sources: [3] [4] [8] [1]

Support access is clearer than response responsibilities

Sterling advertises structured check-ins intended to keep the protocol and broader plan aligned with the patient’s response. It also offers around-the-clock messaging through a private patient portal. The contact page publishes support@sterlingprivatemedical.com and (475) 290-6731, alongside secure messaging described as available 24/7. These are concrete contact paths, but the availability of a messaging channel does not establish immediate access to a prescribing clinician.

The contact form carries a separate promise that the team will respond within 24 hours. That is not a documented clinical-review, prescription, pharmacy-preparation or delivery deadline. The consulted pages also do not specify the frequency of scheduled reviews or who answers each category of portal message. A useful enrollment question is whether billing, side-effect concerns, refill decisions and shipment problems are routed to different teams, and what escalation is available if an issue remains unresolved.

Follow-up should be evaluated as a service commitment, not just an attractive description attached to the fee. NIDDK explains that ongoing care involves response and tolerability, with medication selection taking health conditions, other medicines and costs into account. Sterling’s advertised check-ins fit that general need, but the documents do not establish their actual frequency or clinical outcomes. Request a practical description of routine follow-up and the separate process for concerns that arise between reviews.

Sources: [3] [6] [2]

Privacy promises need to be read with the disclosures

The semaglutide page says medical information is shared only with the physician and dispensing pharmacy, followed by a broad statement that Sterling never sells or shares data. Its California notice adds an important qualification: certain personal information may be made available to third parties for advertising delivery, measurement and improvement, and those disclosures may count as a “sale” or “share” under California law. The broad marketing reassurance is therefore not the whole privacy picture.

These statements concern categories that should not be casually collapsed together. Advertising-related personal information is not necessarily the same as protected medical information. At the same time, the terms say Sterling is not itself a HIPAA covered entity, although it may act as a business associate of a pharmacy or medical group in some circumstances. That status description does not, by itself, answer every question about which information is collected, who receives it or which protections apply.

Before registering, ask for the privacy notices applicable to the platform, treating organization and dispensing pharmacy, along with available advertising-data choices. This review did not consult a separate HIPAA notice, and the available terms text omitted an intermediate section. Those limits prevent a complete account of every contractual provision. A broader checklist of terms to examine before enrollment can help keep privacy, payment authorization and service responsibilities in the same decision rather than treating them as unrelated fine print.

Sources: [8] [3] [7]

Questions & answers

Can I rely on the 48-hour cancellation rule?

Not without resolving the competing language. Sterling’s terms describe disabling auto-refill at least 48 hours before monthly processing, but its treatment page requires 30 days’ notice before the next billing cycle. Ask which provision applies to your subscription and obtain the processing date and cancellation confirmation in writing. Neither provision, by itself, establishes a refund for services begun or medication already processed.

Sources: [8] [3]

Is $169 the complete semaglutide price for everyone?

No. Sterling advertises injectable semaglutide from $169 per month and says final pricing is confirmed after consultation. Medication, supplies, provider care and concierge support are advertised as included, and the semaglutide page says there are no consultation or dose-change surcharges. The documentation does not explain every condition affecting the final quote or clearly settle laboratory, testing and in-person-care costs. Request a patient-specific itemized description.

Sources: [4] [3]

Can Sterling send the prescription to my preferred pharmacy?

Its stated purchase terms do not offer unrestricted pharmacy choice. They require customers buying a prescription-containing service to waive that choice and use a pharmacy accessible through the platform. The documentation reviewed here does not name the dispensing pharmacies. Ask for the pharmacy’s identity before purchase and clarify any concerns about fulfillment, packaging or communication before accepting that restriction.

Sources: [8]

Does Sterling guarantee medication after I complete the assessment?

No. The assessment begins the process, but the terms require a consultation, a provider’s determination that the prescription product is appropriate and an issued prescription. Sterling’s published age and BMI descriptions do not override that decision. Because recurring orders authorize an immediate charge, ask how the payment and refund process works if a clinician does not prescribe; the consulted documentation does not fully answer that scenario.

Sources: [4] [8]

What exactly is the $129 GLP-1 Microdose program?

It is a program advertised from $129 per month with medication, supplies, discreet delivery and concierge support. Sterling describes potential customers as people near goal weight, those who tolerated standard GLP-1 treatment poorly and those pursuing broader hormone or healthy-aging plans. The consulted documentation does not specify the active ingredient or route. Those marketing descriptions are not proof of better tolerability or results, so request the exact proposed product before comparing prices.

Sources: [4] [10]

Does 24/7 concierge support mean an immediate clinical response?

The documented promise is around-the-clock messaging access, not a guaranteed immediate clinician response. Sterling separately says contact-form messages receive a team response within 24 hours. Email and telephone support are also listed. Before enrolling, clarify who monitors treatment questions, what turnaround applies to clinical concerns and how pharmacy problems are escalated. None of these support statements establishes a medication preparation or arrival deadline.

Sources: [3] [6]

Our assessment

Sterling documents a recognizable offering: three GLP-1 program listings, starting prices, bundled payment components, clinician review, partner-pharmacy fulfillment and several support channels. Its explicit acknowledgment of compounded-drug status and description of independent professional responsibilities are useful disclosures. The commercial promise is nevertheless clearer than several enrollment boundaries. The unresolved 30-day versus 48-hour cancellation conflict is particularly important because payments recur every 30 days and some services become nonrefundable once begun or processed. Before authorizing payment, obtain the final quote, applicable cancellation rule, processing date, clinician and pharmacy identities, state availability and follow-up arrangements in writing. Review the relevant privacy notices rather than relying solely on the treatment-page reassurance. Sterling may merit further consideration for adults exploring this model, but the documentation does not establish clinical outcomes, universal access or a fully settled subscription experience.

Visit Sterling Private Medical’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Sterling Private Medical Review: What the GLP-1 Subscription Terms Actually Say

At a glance

01Resolve the cancellation conflict before the first payment

02What the advertised price buys—and what remains unsettled

03The first charge starts a recurring authorization

04A concierge brand with independent care organizations

05Eligibility and geography are conditions, not guarantees

06The pharmacy arrangement limits choice

07Support access is clearer than response responsibilities

08Privacy promises need to be read with the disclosures